LivaNova Encourages Awareness of Drug-Resistant Epilepsy on International Epilepsy Day

"Epilepsy Around the World" Infographic Educates on Drug-Resistant Condition, Which Affects Approximately One in Three People with Epilepsy

HOUSTON, Feb. 8, 2016 /PRNewswire/ -- LivaNova, PLC, maker of the VNS Therapy(®) system, today released an infographic on "Epilepsy Around the World," promoting greater awareness of the disease and encouraging drug-resistant epilepsy to be part of the global discussion on International Epilepsy Day. The new infographic shares important epilepsy statistics from around the world, demonstrating the widespread impact of epilepsy both in terms of the number of people affected and the high cost of the disease. The infographic also shares that, of the nearly 65 million people worldwide with epilepsy, about 1 in 3 people with epilepsy have the type that is difficult to treat with medications. (1,2,3)

LivaNova is dedicated to raising awareness for epilepsy and the treatment for drug-resistant epilepsy and encourages people to join the global conversation about epilepsy on February 8 by visiting []

To view the full infographic in English, click here []. To view the full infographic in French, click here []. To view the full infographic in German, click here [].

About VNS Therapy

VNS (vagus nerve stimulation) Therapy is a unique treatment approach with FDA and CE mark approval specifically developed for the treatment of drug-resistant epilepsy.(4) For more information, visit or []

About LivaNova

LivaNova, PLC, headquartered in London, UK, is a global medical technology company. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Rhythm Management, Cardiac Surgery, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.A.), respectively. To learn more about LivaNova, please visit []

(1) Epilepsy Foundation of America. Who Gets Epilepsy? Accessed Jan. 2016 from

(2) WHO Fact Sheet No. 999: Epilepsy. Accessed June 2014 at

(3) Kwan et al. Epilepsia. 2010 Jun;51(6):1069G77

(4) VNS Therapy Physician's Manual, Pg 4. Cyberonics, Inc., Houston, TX.

LivaNova, PLC

CONTACT: Susan English, Havas PR,,+1-412-512-6547

Web site:

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234